{
  "docId": "019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "docSlug": "714b2223d61a474cc0c3d011e3fc18ab",
  "documentTitle": "Centessa | IPO Presentation Deck | 33 slides",
  "authorId": "centessa",
  "authorName": "Centessa Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 12,
  "pageCount": 33,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes a biological mechanism diagram and a comparative table of clinical/simulated toxicity markers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-ff46-75e9-a6a2-27d0e899d3b8/12",
  "deckHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "deckJsonHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8.json",
  "deckAnchorHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.15,
        "y": 0.5
      },
      "kind": "diagram",
      "text": "Hepatocyte mechanism diagram showing tolvaptan interaction with mitochondria and bile salts",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bd03582-6fa2-44ad-96fc-c721fe01f14d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "list",
      "text": "IN SILICO EVIDENCE: DILIsym (highly predictive quantitative systems toxicology tool) correctly predicted DILI potential of numerous drug pairs, accurately reproduced liver toxicity of tolvaptan, and predicted lixivaptan not likely to cause DILI.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b386258-0d69-4ae8-ae66-297d1fe6b00c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "list",
      "text": "NON-CLINICAL EVIDENCE: Tolvaptan causes DILI via 2 well-known hepatocyte injury mechanisms: disruption of bile acids homeostasis and mitochondrial dysfunction. Long-lived metabolite of tolvaptan contributes to toxicity. Lixivaptan does not share metabolites with tolvaptan.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d061b5c-86cd-4f2e-b63b-968b09099860",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "JYNARQUE (tolvaptan) REMS: Restricted distribution & prescription, frequent blood test monitoring for liver tox. Initial data support thesis that lixivaptan avoids drug-induced liver injury (DILI)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62e8d824-0da0-4d96-aa00-50bf10dc860d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.55,
        "y": 0.65
      },
      "kind": "table",
      "text": "Comparison table of ALT > 3x ULN and Hy's Law cases for Tolvaptan vs Lixivaptan",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b24a6e8-0191-4203-b326-808540378258",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Lixivaptan: Potential for Best-in-Class Profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53abc368-f4ee-47c7-b115-d579774e96a0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "7da477a9-ea87-429d-bd9f-00ab551c5d53",
      "evidence": "Side-by-side comparison of drug profiles and toxicity data",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 11,
      "beatId": "858c031e-6b1f-41e5-b1d3-a2219b0e9631",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck provides data on the market potential of the company's treatments",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}